Takeda Pharmaceutical (TAK) Long-Term Debt Issuances (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Long-Term Debt Issuances of -$70.7 million for Q2 2026, down 105.57% year-over-year from $1.3 billion in Q2 2025, and down 101.94% quarter-over-quarter from $3.6 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Long-Term Debt Issuances (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Long-Term Debt Issuances history runs 10 years deep, the most recent figure standing at -$70.7 million for Q2 2026.
- In Q2 2026, Long-Term Debt Issuances fell 105.57% year-over-year to -$70.7 million; the TTM figure through Jun 2026 stood at $2.6 billion (down 68.01% YoY), while the FY2026 annual figure was $3.9 billion, down 42.11% from the prior year.
- Long-Term Debt Issuances for Q2 2026 stood at -$70.7 million, down from $3.6 billion in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $6.8 billion in Q1 2025, with the low at -$6.5 billion in Q4 2024.
- The 5-year median for Long-Term Debt Issuances is $147.2 million (2023), against an average of $745.3 million.
- Peak annual rise in Long-Term Debt Issuances reached 10483.4% in 2024, while the deepest fall reached 1568.37% in 2024.
- Takeda Pharmaceutical's Long-Term Debt Issuances stood at $110.1 million in 2022, then surged by 304.36% to $445.3 million in 2023, then tumbled by 1568.37% to -$6.5 billion in 2024, then surged by 49.19% to -$3.3 billion in 2025, then soared by 97.87% to -$70.7 million in 2026.
- Business Quant data shows TAK's Long-Term Debt Issuances at -$70.7 million in Q2 2026, $3.6 billion in Q1 2026, and -$3.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.66 Mn |
| Jun 30, 2026 | -70.66 Mn |
| Mar 31, 2026 | 3.64 Bn |
| Mar 31, 2026 | 3.64 Bn |
| Dec 31, 2025 | -3.32 Bn |
| Dec 31, 2025 | -3.32 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Sep 30, 2025 | 2.32 Bn |
| Jun 30, 2025 | 1.27 Bn |
| Jun 30, 2025 | 1.27 Bn |
| Mar 31, 2025 | 6.78 Bn |
| Mar 31, 2025 | 6.78 Bn |
| Dec 31, 2024 | -6.54 Bn |
| Dec 31, 2024 | -6.54 Bn |
| Sep 30, 2024 | 6.54 Bn |
| Sep 30, 2024 | 6.54 Bn |
| Jun 30, 2024 | 57.58 Mn |
| Jun 30, 2024 | 57.58 Mn |
| Dec 31, 2023 | 445.30 Mn |
| Dec 31, 2023 | 445.30 Mn |